Actualités

SPRO strengthens its balance sheet and extends cash runway into 2029 while advancing its new SP001 immunology pipeline following the landmark approval of the first oral carbapenem antibiotic.

Pfizer’s second quarter results reflected stability in its core business despite ongoing challenges in COVID-related product demand. The company’s performance was shaped by strong execution in its non-COVID portfolio, with management highlighting robust revenue contributions from acquired brands and recent launches. CEO Albert Bourla attributed operational progress to “continued strategic progress” and emphasized the value generated by recent acquisitions such as Seagen and Biohaven. Management

The drugmaker's operating numbers are near the top of its class, but its stock performance is lagging the pack. Is the market seeing a risk that the fundamentals are missing.

Management raised its full-year forecast, but the market seems to be asking for more than a higher target.

Bristol Myers growth portfolio now accounts for 56% of revenues, led by key drugs, including Opdivo Qvantig, Reblozyl and Breyanzi, helping offset generic erosion.

PFE's non-COVID products are gaining momentum, with launches, acquisitions and a pipeline aimed at driving growth from 2029 onward.

RAS mutations fuel nearly a third of all cancers, and one biotech has quietly built the deepest late-stage pipeline targeting them. Now the biggest names in pharma are circling, and the math on who can actually write the check gets complicated fast.

The S&P 500's dividend yield just hit a record low, leaving income investors scrambling for alternatives. Five long-established index members still pay 6% or more, and all carry Buy ratings from top Wall Street analysts.

Pfizer (NYSE:PFE) agreed to a US$44 million class action settlement related to its smoking cessation drug Chantix, addressing claims tied to product safety disclosures. The company reported positive topline Phase 3 results for LITFULO in adults and adolescents with nonsegmental vitiligo, highlighting progress in its immunology pipeline. Both developments arrive as investors track Pfizer's legal exposures alongside late stage trial data that could inform future portfolio and revenue...

This healthcare giant is on a serious run, but with the stock trading at a peak, investors must decide if the powerful business engine has more fuel or if the price has already burned it all.

Pfizer sent shareholders a fortune in cash, yet the stock fell far behind the market, forcing a hard question about what all that money truly bought.

This problem has a solution, and Pfizer is implementing it.

Pfizer agreed to a $44 million Chantix settlement. Here's who may qualify, how to file a claim and the deadline to submit.

Both of these stocks pay more than double the S&P 500 average of 1.1%.

BBIO's Q2 loss misses estimates, but revenues beat expectations as Attruby sales more than tripled, fueling growth and pipeline advances.

Non-COVID products surge 5% as Pfizer raises guidance and targets $9.7B in savings.

Pfizer Inc. (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX), two companies forever linked by their historic COVID-19 vaccine partnership, reported Q2 2026 earnings alongside major strategic announcements. While the European Commission authorized their updated XFG-adapted COVID-19 vaccine on July 29, the two partners are traveling down very different paths. One is leveraging massive scale and aggressive cost-cutting […]

Eli Lilly's growth is huge, but on its latest call, analysts tested whether the next chapter can possibly live up to the last one.

S&P 500 companies' quarterly earnings growth rate eased from a week ago amid a drop in the healthcar

The stock's 6.4% yield is attractive, but it comes with risk.

The case for more upside rests on its obesity pill, and what changed is not the drug but who can now write it and who can now pay for it.

Bristol Myers Squibb's Growth Portfolio and pipeline support momentum, but generic headwinds and recent gains call for a cautious stance.

Pfizer's Q2 beat and raised 2026 revenue outlook signal progress, but declining COVID sales and patent losses challenge its growth path.

In early August 2026, Novavax reported Q2 2026 revenue of US$56.7 million, sharply lower than the prior year, and moved from net income to a net loss of US$53.39 million, translating into basic and diluted losses of US$0.32 per share from continuing operations. Alongside the weak year-on-year comparisons, Novavax beat analyst expectations for both revenue and earnings and highlighted progress on high-profile partnerships, including Sanofi and Pfizer, while also filing an US$82.47 million...

Berobenatide is one of the keys to Pfizer's future.

If you hold shares, you're already exposed to a potential future where the stock is either far higher or far lower, and the options market is pricing both as real possibilities.

Novavax beat Q2 earnings and revenue estimates, raises its 2026 adjusted revenue outlook, cuts expense guidance and outlines potential Sanofi milestones ahead.

Volatility in the stock market and the Magnificent Seven dominate the headlines. Investors are repositioning toward more value-based funds.

Novavax secures key partnerships and raises 2026 outlook while advancing its adjuvant platform in infectious disease and oncology.

Novavax raised its full-year 2026 adjusted total revenue outlook to $235–$275 million from $230–$270 million.